Immunome, Inc. (NASDAQ:IMNM) Sees Large Decline in Short Interest

Immunome, Inc. (NASDAQ:IMNM) was the target of a large drop in short interest in January. As of January 15th, there was short interest totaling 15,314,650 shares, a drop of 12.6% from the December 31st total of 17,532,234 shares. Based on an average trading volume of 2,451,335 shares, the short-interest ratio is presently 6.2 days. Approximately 18.1% of the shares of the company are short sold. Approximately 18.1% of the shares of the company are short sold. Based on an average trading volume of 2,451,335 shares, the short-interest ratio is presently 6.2 days.

Insider Activity at Immunome

In other news, CEO Clay B. Siegall bought 4,729 shares of the business’s stock in a transaction on Tuesday, December 30th. The shares were bought at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the acquisition, the chief executive officer owned 665,254 shares in the company, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Philip Tsai acquired 10,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was bought at an average price of $20.49 per share, with a total value of $204,900.00. Following the acquisition, the insider directly owned 43,300 shares in the company, valued at $887,217. This represents a 30.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 68,518 shares of company stock worth $1,453,958 in the last 90 days. 7.69% of the stock is owned by company insiders.

Institutional Trading of Immunome

Several institutional investors have recently added to or reduced their stakes in the company. Nan Fung Trinity HK Ltd. lifted its position in shares of Immunome by 20.7% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock worth $15,349,000 after purchasing an additional 122,450 shares during the period. Strs Ohio purchased a new position in shares of Immunome in the 4th quarter worth about $64,000. Vanguard Group Inc. boosted its holdings in shares of Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the period. Arizona State Retirement System grew its position in shares of Immunome by 27.1% in the 4th quarter. Arizona State Retirement System now owns 26,104 shares of the company’s stock worth $561,000 after buying an additional 5,568 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Immunome in the 4th quarter worth $3,652,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Price Performance

NASDAQ IMNM opened at $26.97 on Wednesday. Immunome has a 12 month low of $5.15 and a 12 month high of $27.23. The company has a 50-day moving average of $21.63 and a 200-day moving average of $15.81. The company has a market cap of $2.47 billion, a P/E ratio of -9.14 and a beta of 2.32.

Immunome (NASDAQ:IMNM) last released its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, equities research analysts anticipate that Immunome will post -2.21 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on IMNM shares. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Immunome in a report on Thursday, January 15th. Guggenheim lifted their price target on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Lake Street Capital lifted their price objective on shares of Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Finally, Evercore ISI increased their target price on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Immunome currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.